Disney is reporting its fiscal third-quarter results and the average analysts' view is for earnings of 93 cents a share on revenue of $11.30 billion. One of the best blue chips in 2012, Disney shares have jumped more than 30% since the start of the year with the company delivering a 5% beat in its fiscal second quarter because of the success of The Avengers and the strength of the parks and resorts business, which saw year-over-year jumps of 10% in revenue and 53% in segment operating income. Other companies reporting before the bell include Amedisys ( AMED), Bridgepoint Education ( BPI), Cablevision ( CVC), Church & Dwight ( CHD), CVS Corp. ( CVS), EDGAR Online ( EDGR), FirstEnergy ( FE), Fossil ( FOSL), Hecla Mining ( HL), Intercontinental Hotels Group ( IHG), Lifetime Brands ( LCUT), Marsh & Mclennan ( MMC), MGM Resorts International ( MGM), Molson Coors Brewing ( TAP), Office Depot ( ODP), Pantry ( PTRY), PG&E Corp. ( PGE), Spectrum Brands ( SPB) and Tenet Healthcare ( THC). After the close, results from A123 Systems ( AONE), Buckeye Technologies ( BKI), Chiquita Brands International ( CQB), Coca-Cola Bottling ( COKE), Cree ( CREE), Demand Media ( DMD), Jazz Pharmaceuticals ( JAZZ), Jive Software ( JIVE), Learning Tree International ( LTRE), Maiden Holdings ( MHLD), Rackspace Hosting ( RAX), Red Lion Hotels ( RLH), Sonus Networks ( SONS), Vitesse Semiconductor ( VTSS) and Zillow ( Z) are slated to hit the tape. The economic calendar features is barren except for consumer credit for June, due at 3 p.m. ET. The consensus view, according to Briefing.com, is for a $10 billion increase on the heels of May's surprising $17.1 billion jump. And finally, shares of Dow components Johnson & Johnson ( JNJ) and Pfizer ( PFE) were coming under some selling pressure following news of the discontinuation of development of bapineuzumab intravenous, a proposed treatment for mild-to-moderate Alzheimer's disease, after a disappointing phase III trial. The two companies were partners on the drug's development as was Elan ( ELN), which has a 49.9% interest in Janssen AI, the J&J unit that was working with Pfizer on the drug. Elan shares were falling more than 8% in late trades to $10.30 on volume of close to 700,000. Elan said it expects to record a non-cash impairment charge of $117.3 million in the third quarter to write down the entire value of its Janssen AI investment. Pfizer shares were last quoted at $23.80, down 1.9%, on volume of nearly 200,000, according to Nasdaq.com, while J&J's stock was sliding less than 1% at $63.80 on volume of more than 125,000. Leap Wireless ( LEAP) was also a big mover to the downside, tumbling more than 10% after the company reported a wider than anticipated loss in the second quarter. The San Diego-based provider of wireless communications services posted a loss of $46 million, or 54 cents a share, on revenue of $786.8 million, missing the average estimate of analysts polled by Thomson Reuters for a loss of 50 cents a share on revenue of $836.3 million. -- Written by Michael Baron in New York. >To contact the writer of this article, click here: Michael Baron.